MIRIAM MEDINA: Open Payments
NPI 1558037275 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,655 in 56 payments from 18 companies in 2025. Trend: 2023 $434 · 2024 $1,211 · 2025 $1,655
Food & beverage: $1,655
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | $272 |
| AstraZeneca Pharmaceuticals LP | 5 | $208 |
| ARS Pharmaceuticals Operations, Inc. | 12 | $190 |
| CSL Behring | 9 | $184 |
| REVANCE THERAPEUTICS, INC. | 1 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $130 |
| Blueprint Medicines Corporation | 1 | $121 |
| GlaxoSmithKline, LLC. | 5 | $107 |
| ADMA BioManufacturing LLC | 1 | $91 |
| Ionis Pharmaceuticals, Inc. | 2 | $45 |
Products named: Rhapsido, NEFFY, FASENRA, DAXI, AYVAKIT, Andembry, TRELEGY ELLIPTA, CUVITRU.
Industry payments across TX — which companies pay providers there.
